智通财经APP获悉，2月13日，南京诺令生物科技股份有限公司("诺令生物")向港交所主板递交上市申请，建银国际为独家保荐人。招股书显示，诺令生物专 注于一氧化氮吸入(iNO)疗法的研发与商业化应用。依托气液精密控制技术平台，诺令生物已建立起覆盖一氧化氮(NO)发生、传输、检测、储存和临床应用 的全链路技术的能力。根据弗若斯特沙利文的资料，诺令生物是全球少数能够实现NO全链路技术自主可控的企业之一，也是全球唯一覆盖NO治疗与诊断应 用全面产品线的企业。 公司简介 截至最后实际可行日期，诺令生物拥有5款已获批产品及4款在研候选产品，涵盖心肺诊疗领域的重症监护、病房、门诊及居家疾病管理，包括三大产品线： (i) iNO疗法;(ii)心肺循环支持;及(iii) 呼气诊断。 诺令生物的所有产品均为内部自主研发，且该公司拥有所有产品及候选产品的全球独家权利。诺令生物的核心产品iNOwill于2022年获国家药监局批准、 2025年获欧盟 CE认证，主要用于肺动脉高压等严重心肺疾病的急性重症监护。根据弗若斯特沙利文的资料，iNOwill是全球首款获批上市的电化学催化法 iNO治疗仪、也是中国首台获批上市的便携式iNO设备， ...

Group 1 - The company, Changchun Gaoxin, stated that the specifics of the medical insurance negotiation depend on government policies and final results, and currently, there is no detailed information available to share [2]

格隆汇2月13日｜Moderna第四季度营收6.78亿美元，同比下降30%，市场预期6.251亿美元。第四季度每 股亏损2.11美元，去年同期每股亏损2.91美元。预计全年营收同比增长最高可达10%。预计全年资本支 出为2亿至3亿美元，市场预期为2.653亿美元。 ...

智通财经APP获悉，2月13日，南京诺令生物科技股份有限公司("诺令生物")向港交所主板递交上市申请，建银国际为独家保荐人。招股书显示，诺令 生物专注于一氧化氮吸入(iNO)疗法的研发与商业化应用。依托气液精密控制技术平台，诺令生物已建立起覆盖一氧化氮(NO)发生、传输、检测、储存 和临床应用的全链路技术的能力。根据弗若斯特沙利文的资料，诺令生物是全球少数能够实现NO全链路技术自主可控的企业之一，也是全球唯一覆盖 NO治疗与诊断应用全面产品线的企业。 ...

莫德纳：该公司目标是到2026年实现相较于2025年营收最高达10%的增长。 来源：滚动播报 ...

据港交所文件，2月13日，南京诺令生物科技股份有限公司向港交所提交上市申请书，独家保荐人为建 银国际。 ...

Core Viewpoint - Kintor Pharmaceutical (02171.HK) has signed a strategic cooperation agreement with Shanghai Jinkong Enterprise Development to invest up to 370 million yuan in building a CAR-T cell therapy product commercialization production base in Shanghai's Jinshan District, aligning with the commercialization process of multiple CAR-T products [1][2]. Group 1: Investment and Production Base - The total investment for the new CAR-T drug production base is capped at 370 million yuan, with the construction managed by Shanghai Jinkong [1]. - The investment will be executed through a phased payment model, allowing Kintor to retain cash flow for core R&D and new drug promotion [3]. - The construction is expected to take 14 months, with Kintor making quarterly service fee payments during the initial years [3]. Group 2: Product Development and Market Potential - Kintor's CAR-T product, Shurui Kiorunai, is currently under review for market approval and is the first entity-targeting CAR-T product to submit a New Drug Application in China [2]. - The product targets Claudin18.2 positive advanced gastric/esophageal junction adenocarcinoma, with clinical trial results showing superior efficacy compared to existing therapies [2]. - The market for gastric cancer treatment is significant, with 358,700 new cases and 260,400 deaths reported in 2022 in China, indicating a high demand for effective therapies [2]. Group 3: Financial Performance - Kintor expects a significant reduction in net losses, projecting a loss of no more than 120 million yuan for the reporting period, down from 798 million yuan in the previous year [4]. - The reduction in losses is attributed to increased commercialization revenue from the existing product, Zewokiorunai, and decreased R&D expenditures for both Zewokiorunai and Shurui Kiorunai [4]. - As of June 30, 2025, Kintor reported cash and bank balances of approximately 1.261 billion yuan, indicating sufficient cash flow until 2028 without considering future inflows [3].

Core Viewpoint - The Hang Seng Index Company announced the results of the quarterly review for the Hang Seng Index series, with Valiant Bio-B (09887) being included in the Hang Seng Composite Index, effective from March 9, 2026 [1] Group 1: Company Updates - Valiant Bio-B is likely to be included in the Stock Connect program due to meeting various criteria such as market capitalization, liquidity, and listing duration [1] - The company announced that the first patient has successfully received treatment in the Phase Ib/II clinical trial of its PD-L1/4-1BB bispecific antibody, Opalizumab (LBL-024), for recurrent or metastatic triple-negative breast cancer [1] - The open-label, multicenter Phase Ib/II clinical study is led by Professor Yin Yongmei from Jiangsu Provincial People's Hospital and is being conducted simultaneously at multiple hospitals across the country [1] Group 2: Clinical Research - The trial aims to evaluate the efficacy and safety of Opalizumab administered alone or in combination with albumin-bound paclitaxel in patients with recurrent or metastatic triple-negative breast cancer [1]

Core Viewpoint - Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of December 31, 2025, with Kintor Pharmaceutical-B (02171) being included in the Hang Seng Composite Index, effective after market close on March 6, 2026, and effective from March 9, 2026 [1] Group 1 - Kintor Pharmaceutical-B is likely to be included in the Stock Connect program due to meeting various criteria such as market capitalization, liquidity, and listing duration [1] - Kintor Pharmaceutical-B announced a strategic cooperation agreement on February 12, 2026, through its wholly-owned subsidiary, Shanghai Kexing Diagnostics, with Shanghai Jinguang Enterprise Development, a key platform enterprise in Shanghai's Jinshan District [1] - The total investment for the strategic cooperation is not to exceed RMB 370 million, aimed at establishing an advanced CAR-T cell therapy product commercialization production base in Jinshan District, Shanghai [1]

格隆汇2月13日丨三生国健(688336.SH)公布，公司的抗IL-17A人源化单克隆抗体安沐奇塔单抗注射液 （商品名：益赛拓®，以下简称"安沐奇塔单抗"）的新药上市申请已经获得国家药品监督管理局批准， 用于治疗适合系统治疗或光疗的中度至重度斑块状银屑病成人患者。 安沐奇塔单抗具有皮损清除能力强且起效快、免疫原性低、安全性和耐受性良好、给药便捷性高等多方 面的核心优势，已得到了多个大样本量临床研究数据的充分验证。 ...